Citation 99244

FURUSAWA,E: SUZUKI,M: FURUSAWA,S: LEE,JYB:. (1975). COMBINATION CHEMOTHERAPY OF RAUSCHER LEUKEMIA AND ASCITES TUMORS BY NARCISSUS ALKALOID WITH STANDARD DRUGS AND EFFECT ON CELLULAR IMMUNITY (38896).. 149()

Citation Details

Title	COMBINATION CHEMOTHERAPY OF RAUSCHER LEUKEMIA AND ASCITES TUMORS BY NARCISSUS ALKALOID WITH STANDARD DRUGS AND EFFECT ON CELLULAR IMMUNITY (38896).
Authors	FURUSAWA,E: SUZUKI,M: FURUSAWA,S: LEE,JYB:
Year	1975
Volume	149
Issue

Summary

Year: 1975

Journal: Unknown

Organisms and Their Experiments (1)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
2	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	EMETINE,(-):	WEAK ACTIVITY
3	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	LEUROCRISTINE	INACTIVE
4	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)ANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DAUNORUBICIN	INACTIVE
5	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)ANTICANCER AND/OR CYTOTOXICITY MARKER CODE	ACTINOMYCIN D	ACTIVE
6	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
7	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
8	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
9	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
10	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
11	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
12	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
13	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
14	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
15	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	TAZETTINE,PRE:	ACTIVE
16	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	EMETINE,(-):	ACTIVE
17	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	LEUROCRISTINE	ACTIVE
18	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)ANTICANCER AND/OR CYTOTOXICITY MARKER CODE	ACTINOMYCIN D	ACTIVE
19	ANTITUMOR ACTIVITY	EFFECTS DUE TO A COMBINATION OF DRUGSPHARMACOLOGY OF COMPOUND - IN VIVOANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)ANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DAUNORUBICIN	ACTIVE

Show SPARQL Queries (1)